The Experts below are selected from a list of 939 Experts worldwide ranked by ideXlab platform

Anthony H. Cincotta - One of the best experts on this subject based on the ideXlab platform.

  • IDENTIFICATION OF HEPATIC, NON-MONOAMINE, Dihydroergocryptine BINDING SITES WITH SIGNIFICANT GENDER DIFFERENCES
    Life Sciences, 1996
    Co-Authors: Alexander Y. Korneyev, Anthony H. Cincotta
    Abstract:

    Abstract High affinity [3H] Dihydroergocryptine binding sites different from α 1 α 2 - adreno , dopamine or serotonin receptors were detected in a crude membrane fraction from hamster liver by radioligand binding filtration assay. The binding was saturable and reversible, as well as time and protein dependent. Scatchard analysis revealed a single population of binding sites with Kd 3.8 ± 0.9 nM and Bmax = 675 ± 130 pmol/g tissue (mean ± S.E.M., n = 6) in the male hamster crude liver membrane fraction. In the female liver membranes the Kd value was 4.4 + 1.2 nM and Bmax = 1025 ± 190 pmol/g tissue (mean + S.E.M., n = 6). Differences between males and females in Bmax values are significant (P ergotamine > Dihydroergocryptine > dihydroergocristine > α ergocristine > dihidroergotamine > ergocornine > ergocristine > nicardipine > (+) butaclamol > PK 11195 > nitrendipine > domperidone > (-)butaclamol (in order of decreasing affinity). The described type of Dihydroergocryptine binding sites was not detected in hamster brain, kidney, spleen or lungs. Obtained data support the concept that some ergot-derivatives may induce metabolic effects in the liver through peripheral mechanisms other than those, mediated by α-adrenoreceptors.

  • IDENTIFICATION OF HEPATIC, NON-MONOAMINE, Dihydroergocryptine BINDING SITES WITH SIGNIFICANT GENDER DIFFERENCES
    Life Sciences, 1996
    Co-Authors: Alexander Y. Korneyev, Anthony H. Cincotta
    Abstract:

    Abstract High affinity [3H] Dihydroergocryptine binding sites different from α 1 α 2 - adreno , dopamine or serotonin receptors were detected in a crude membrane fraction from hamster liver by radioligand binding filtration assay. The binding was saturable and reversible, as well as time and protein dependent. Scatchard analysis revealed a single population of binding sites with Kd 3.8 ± 0.9 nM and Bmax = 675 ± 130 pmol/g tissue (mean ± S.E.M., n = 6) in the male hamster crude liver membrane fraction. In the female liver membranes the Kd value was 4.4 + 1.2 nM and Bmax = 1025 ± 190 pmol/g tissue (mean + S.E.M., n = 6). Differences between males and females in Bmax values are significant (P ergotamine > Dihydroergocryptine > dihydroergocristine > α ergocristine > dihidroergotamine > ergocornine > ergocristine > nicardipine > (+) butaclamol > PK 11195 > nitrendipine > domperidone > (-)butaclamol (in order of decreasing affinity). The described type of Dihydroergocryptine binding sites was not detected in hamster brain, kidney, spleen or lungs. Obtained data support the concept that some ergot-derivatives may induce metabolic effects in the liver through peripheral mechanisms other than those, mediated by α-adrenoreceptors.

G. Reboldi - One of the best experts on this subject based on the ideXlab platform.

  • Alpha‐Dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study
    Acta neurologica Scandinavica, 2009
    Co-Authors: Leontino Battistin, P. G. Bardin, F. Ferro-milone, C. Ravenna, V. Toso, G. Reboldi
    Abstract:

    INTRODUCTION A multicentre randomized double-blind parallel group study was carried out on 68 patients suffering from idiopathic Parkinson's disease (PD) treated with L-dopa for at least 1 year with inadequate therapeutic responsiveness. The aim of the study was to compare the efficacy of alpha-Dihydroergocryptine (alpha-DHEC) vs lisuride as an adjunct therapy to L-dopa on dyskinesias and clinical fluctuations (Unified Parkinson's Disease Rating Scale [UPDRS] part IV), on the symptoms pattern (Columbia University Rating Scale [CURS]), on disability (Northwestern University Disability Scale [NUDS]), and to evaluate the incidence of adverse events. PATIENTS AND METHODS Thirty-two patients (18 males, 14 females with a mean age of 64.5+/-1.5 SEM) were randomized to alpha-Dihydroergocryptine and 36 (16 males, 20 females with a mean age of 61.8+/-1.4) to lisuride. The treatment lasted 3 months and the dosage was increased until it reached 60 mg/day of alpha-Dihydroergocryptine and 1.2 mg/day of lisuride, while the L-dopa dosage was kept constant in both groups. Per protocol and intention to treat analyses were performed on response variables. RESULTS The adjunctive treatment with the two dopamine agonists determined a significant improvement of PD symptoms in both groups. Alpha-Dihydroergocryptine showed a superior efficacy in reducing the clinical complications (P < 0.01 by ANOVA). The number of patients complaining of adverse events was 8 out of 32 (25%) for alpha-Dihydroergocryptine and 24/36 (67%) for lisuride (P < 0.05). CONCLUSION Alpha-Dihydroergocryptine effect seems to be superior to that of lisuride both in terms of reduction of L-dopa therapy long term motor complications (UPDRS part IV) as well as in terms of the incidence and severity of adverse events.

  • alpha Dihydroergocryptine in parkinson s disease a multiceuntre randomized double blind parallel group study
    Acta Neurologica Scandinavica, 2009
    Co-Authors: Leontino Battistin, P. G. Bardin, C. Ravenna, V. Toso, F Ferromilone, G. Reboldi
    Abstract:

    INTRODUCTION A multicentre randomized double-blind parallel group study was carried out on 68 patients suffering from idiopathic Parkinson's disease (PD) treated with L-dopa for at least 1 year with inadequate therapeutic responsiveness. The aim of the study was to compare the efficacy of alpha-Dihydroergocryptine (alpha-DHEC) vs lisuride as an adjunct therapy to L-dopa on dyskinesias and clinical fluctuations (Unified Parkinson's Disease Rating Scale [UPDRS] part IV), on the symptoms pattern (Columbia University Rating Scale [CURS]), on disability (Northwestern University Disability Scale [NUDS]), and to evaluate the incidence of adverse events. PATIENTS AND METHODS Thirty-two patients (18 males, 14 females with a mean age of 64.5+/-1.5 SEM) were randomized to alpha-Dihydroergocryptine and 36 (16 males, 20 females with a mean age of 61.8+/-1.4) to lisuride. The treatment lasted 3 months and the dosage was increased until it reached 60 mg/day of alpha-Dihydroergocryptine and 1.2 mg/day of lisuride, while the L-dopa dosage was kept constant in both groups. Per protocol and intention to treat analyses were performed on response variables. RESULTS The adjunctive treatment with the two dopamine agonists determined a significant improvement of PD symptoms in both groups. Alpha-Dihydroergocryptine showed a superior efficacy in reducing the clinical complications (P < 0.01 by ANOVA). The number of patients complaining of adverse events was 8 out of 32 (25%) for alpha-Dihydroergocryptine and 24/36 (67%) for lisuride (P < 0.05). CONCLUSION Alpha-Dihydroergocryptine effect seems to be superior to that of lisuride both in terms of reduction of L-dopa therapy long term motor complications (UPDRS part IV) as well as in terms of the incidence and severity of adverse events.

Alexander Y. Korneyev - One of the best experts on this subject based on the ideXlab platform.

  • IDENTIFICATION OF HEPATIC, NON-MONOAMINE, Dihydroergocryptine BINDING SITES WITH SIGNIFICANT GENDER DIFFERENCES
    Life Sciences, 1996
    Co-Authors: Alexander Y. Korneyev, Anthony H. Cincotta
    Abstract:

    Abstract High affinity [3H] Dihydroergocryptine binding sites different from α 1 α 2 - adreno , dopamine or serotonin receptors were detected in a crude membrane fraction from hamster liver by radioligand binding filtration assay. The binding was saturable and reversible, as well as time and protein dependent. Scatchard analysis revealed a single population of binding sites with Kd 3.8 ± 0.9 nM and Bmax = 675 ± 130 pmol/g tissue (mean ± S.E.M., n = 6) in the male hamster crude liver membrane fraction. In the female liver membranes the Kd value was 4.4 + 1.2 nM and Bmax = 1025 ± 190 pmol/g tissue (mean + S.E.M., n = 6). Differences between males and females in Bmax values are significant (P ergotamine > Dihydroergocryptine > dihydroergocristine > α ergocristine > dihidroergotamine > ergocornine > ergocristine > nicardipine > (+) butaclamol > PK 11195 > nitrendipine > domperidone > (-)butaclamol (in order of decreasing affinity). The described type of Dihydroergocryptine binding sites was not detected in hamster brain, kidney, spleen or lungs. Obtained data support the concept that some ergot-derivatives may induce metabolic effects in the liver through peripheral mechanisms other than those, mediated by α-adrenoreceptors.

  • IDENTIFICATION OF HEPATIC, NON-MONOAMINE, Dihydroergocryptine BINDING SITES WITH SIGNIFICANT GENDER DIFFERENCES
    Life Sciences, 1996
    Co-Authors: Alexander Y. Korneyev, Anthony H. Cincotta
    Abstract:

    Abstract High affinity [3H] Dihydroergocryptine binding sites different from α 1 α 2 - adreno , dopamine or serotonin receptors were detected in a crude membrane fraction from hamster liver by radioligand binding filtration assay. The binding was saturable and reversible, as well as time and protein dependent. Scatchard analysis revealed a single population of binding sites with Kd 3.8 ± 0.9 nM and Bmax = 675 ± 130 pmol/g tissue (mean ± S.E.M., n = 6) in the male hamster crude liver membrane fraction. In the female liver membranes the Kd value was 4.4 + 1.2 nM and Bmax = 1025 ± 190 pmol/g tissue (mean + S.E.M., n = 6). Differences between males and females in Bmax values are significant (P ergotamine > Dihydroergocryptine > dihydroergocristine > α ergocristine > dihidroergotamine > ergocornine > ergocristine > nicardipine > (+) butaclamol > PK 11195 > nitrendipine > domperidone > (-)butaclamol (in order of decreasing affinity). The described type of Dihydroergocryptine binding sites was not detected in hamster brain, kidney, spleen or lungs. Obtained data support the concept that some ergot-derivatives may induce metabolic effects in the liver through peripheral mechanisms other than those, mediated by α-adrenoreceptors.

Leontino Battistin - One of the best experts on this subject based on the ideXlab platform.

  • Alpha‐Dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study
    Acta neurologica Scandinavica, 2009
    Co-Authors: Leontino Battistin, P. G. Bardin, F. Ferro-milone, C. Ravenna, V. Toso, G. Reboldi
    Abstract:

    INTRODUCTION A multicentre randomized double-blind parallel group study was carried out on 68 patients suffering from idiopathic Parkinson's disease (PD) treated with L-dopa for at least 1 year with inadequate therapeutic responsiveness. The aim of the study was to compare the efficacy of alpha-Dihydroergocryptine (alpha-DHEC) vs lisuride as an adjunct therapy to L-dopa on dyskinesias and clinical fluctuations (Unified Parkinson's Disease Rating Scale [UPDRS] part IV), on the symptoms pattern (Columbia University Rating Scale [CURS]), on disability (Northwestern University Disability Scale [NUDS]), and to evaluate the incidence of adverse events. PATIENTS AND METHODS Thirty-two patients (18 males, 14 females with a mean age of 64.5+/-1.5 SEM) were randomized to alpha-Dihydroergocryptine and 36 (16 males, 20 females with a mean age of 61.8+/-1.4) to lisuride. The treatment lasted 3 months and the dosage was increased until it reached 60 mg/day of alpha-Dihydroergocryptine and 1.2 mg/day of lisuride, while the L-dopa dosage was kept constant in both groups. Per protocol and intention to treat analyses were performed on response variables. RESULTS The adjunctive treatment with the two dopamine agonists determined a significant improvement of PD symptoms in both groups. Alpha-Dihydroergocryptine showed a superior efficacy in reducing the clinical complications (P < 0.01 by ANOVA). The number of patients complaining of adverse events was 8 out of 32 (25%) for alpha-Dihydroergocryptine and 24/36 (67%) for lisuride (P < 0.05). CONCLUSION Alpha-Dihydroergocryptine effect seems to be superior to that of lisuride both in terms of reduction of L-dopa therapy long term motor complications (UPDRS part IV) as well as in terms of the incidence and severity of adverse events.

  • alpha Dihydroergocryptine in parkinson s disease a multiceuntre randomized double blind parallel group study
    Acta Neurologica Scandinavica, 2009
    Co-Authors: Leontino Battistin, P. G. Bardin, C. Ravenna, V. Toso, F Ferromilone, G. Reboldi
    Abstract:

    INTRODUCTION A multicentre randomized double-blind parallel group study was carried out on 68 patients suffering from idiopathic Parkinson's disease (PD) treated with L-dopa for at least 1 year with inadequate therapeutic responsiveness. The aim of the study was to compare the efficacy of alpha-Dihydroergocryptine (alpha-DHEC) vs lisuride as an adjunct therapy to L-dopa on dyskinesias and clinical fluctuations (Unified Parkinson's Disease Rating Scale [UPDRS] part IV), on the symptoms pattern (Columbia University Rating Scale [CURS]), on disability (Northwestern University Disability Scale [NUDS]), and to evaluate the incidence of adverse events. PATIENTS AND METHODS Thirty-two patients (18 males, 14 females with a mean age of 64.5+/-1.5 SEM) were randomized to alpha-Dihydroergocryptine and 36 (16 males, 20 females with a mean age of 61.8+/-1.4) to lisuride. The treatment lasted 3 months and the dosage was increased until it reached 60 mg/day of alpha-Dihydroergocryptine and 1.2 mg/day of lisuride, while the L-dopa dosage was kept constant in both groups. Per protocol and intention to treat analyses were performed on response variables. RESULTS The adjunctive treatment with the two dopamine agonists determined a significant improvement of PD symptoms in both groups. Alpha-Dihydroergocryptine showed a superior efficacy in reducing the clinical complications (P < 0.01 by ANOVA). The number of patients complaining of adverse events was 8 out of 32 (25%) for alpha-Dihydroergocryptine and 24/36 (67%) for lisuride (P < 0.05). CONCLUSION Alpha-Dihydroergocryptine effect seems to be superior to that of lisuride both in terms of reduction of L-dopa therapy long term motor complications (UPDRS part IV) as well as in terms of the incidence and severity of adverse events.

P. G. Bardin - One of the best experts on this subject based on the ideXlab platform.

  • Alpha‐Dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study
    Acta neurologica Scandinavica, 2009
    Co-Authors: Leontino Battistin, P. G. Bardin, F. Ferro-milone, C. Ravenna, V. Toso, G. Reboldi
    Abstract:

    INTRODUCTION A multicentre randomized double-blind parallel group study was carried out on 68 patients suffering from idiopathic Parkinson's disease (PD) treated with L-dopa for at least 1 year with inadequate therapeutic responsiveness. The aim of the study was to compare the efficacy of alpha-Dihydroergocryptine (alpha-DHEC) vs lisuride as an adjunct therapy to L-dopa on dyskinesias and clinical fluctuations (Unified Parkinson's Disease Rating Scale [UPDRS] part IV), on the symptoms pattern (Columbia University Rating Scale [CURS]), on disability (Northwestern University Disability Scale [NUDS]), and to evaluate the incidence of adverse events. PATIENTS AND METHODS Thirty-two patients (18 males, 14 females with a mean age of 64.5+/-1.5 SEM) were randomized to alpha-Dihydroergocryptine and 36 (16 males, 20 females with a mean age of 61.8+/-1.4) to lisuride. The treatment lasted 3 months and the dosage was increased until it reached 60 mg/day of alpha-Dihydroergocryptine and 1.2 mg/day of lisuride, while the L-dopa dosage was kept constant in both groups. Per protocol and intention to treat analyses were performed on response variables. RESULTS The adjunctive treatment with the two dopamine agonists determined a significant improvement of PD symptoms in both groups. Alpha-Dihydroergocryptine showed a superior efficacy in reducing the clinical complications (P < 0.01 by ANOVA). The number of patients complaining of adverse events was 8 out of 32 (25%) for alpha-Dihydroergocryptine and 24/36 (67%) for lisuride (P < 0.05). CONCLUSION Alpha-Dihydroergocryptine effect seems to be superior to that of lisuride both in terms of reduction of L-dopa therapy long term motor complications (UPDRS part IV) as well as in terms of the incidence and severity of adverse events.

  • alpha Dihydroergocryptine in parkinson s disease a multiceuntre randomized double blind parallel group study
    Acta Neurologica Scandinavica, 2009
    Co-Authors: Leontino Battistin, P. G. Bardin, C. Ravenna, V. Toso, F Ferromilone, G. Reboldi
    Abstract:

    INTRODUCTION A multicentre randomized double-blind parallel group study was carried out on 68 patients suffering from idiopathic Parkinson's disease (PD) treated with L-dopa for at least 1 year with inadequate therapeutic responsiveness. The aim of the study was to compare the efficacy of alpha-Dihydroergocryptine (alpha-DHEC) vs lisuride as an adjunct therapy to L-dopa on dyskinesias and clinical fluctuations (Unified Parkinson's Disease Rating Scale [UPDRS] part IV), on the symptoms pattern (Columbia University Rating Scale [CURS]), on disability (Northwestern University Disability Scale [NUDS]), and to evaluate the incidence of adverse events. PATIENTS AND METHODS Thirty-two patients (18 males, 14 females with a mean age of 64.5+/-1.5 SEM) were randomized to alpha-Dihydroergocryptine and 36 (16 males, 20 females with a mean age of 61.8+/-1.4) to lisuride. The treatment lasted 3 months and the dosage was increased until it reached 60 mg/day of alpha-Dihydroergocryptine and 1.2 mg/day of lisuride, while the L-dopa dosage was kept constant in both groups. Per protocol and intention to treat analyses were performed on response variables. RESULTS The adjunctive treatment with the two dopamine agonists determined a significant improvement of PD symptoms in both groups. Alpha-Dihydroergocryptine showed a superior efficacy in reducing the clinical complications (P < 0.01 by ANOVA). The number of patients complaining of adverse events was 8 out of 32 (25%) for alpha-Dihydroergocryptine and 24/36 (67%) for lisuride (P < 0.05). CONCLUSION Alpha-Dihydroergocryptine effect seems to be superior to that of lisuride both in terms of reduction of L-dopa therapy long term motor complications (UPDRS part IV) as well as in terms of the incidence and severity of adverse events.